Thomson Reuters

Data Aims to Help Pharma Firms Pinpoint Repositioning Potential

Information from Thomson Reuters is designed to help drug companies locate drugs with repositioning potential, in order to increase profitability.

With more than 2,000 drugs reintroduced for alternative purposes to date, drug repositioning has become a viable solution for pharmaceutical companies to generate additional revenue. The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, provided deeper insight today into the unique approach its Life Sciences consulting service takes in analyzing drugs and drug candidates to identify those with potential for repositioning.

No votes yet
Syndicate content